The precision medicine pilot
The precision medicine pilot activity was carried out by IMEGEN along with Aarhus University. The IMEGEN product on which the pilot has focused is called IMExoma, a specific DNA sequencing technique. The chosen tool has the been the End User Experience Advisory Panel, involving patients and doctors.
The pilot consisted of three main phases. In the first phase, 11 participants (5 doctors and 6 patients) took part in a half-day meeting in Madrid. The discussion, in the form of a focus group, evolved around the product life cycle as perceived by the participants. In the second phase, the focus group outcomes were discussed during a IMEGEN internal meeting, which led to the definition of 8 actions that the company can implement. An online questionnaire was then provided to all participants, with the aim of collecting feedback on the proposed actions. The third phase consisted of a webinar presenting survey’s outcomes to participants, and summarizing project next steps.
Francesco Lescai from Aarhus University describes the outcomes of the pilot and its benefit for the company
The pilot has resulted in eight very concrete actions that the company is going to implement in the next future. One of these actions has been a concrete input in the design of the product: so, the final report of the diagnostic product will change according to some suggestions that the End User Advisory Panel has provided to the company. In general, these eight actions embraced three different categories: awareness, training and communication.
The pilot has provided an opportunity for the company to build better strategies and anticipate trends – form a technology point of view but also in terms of market trends and needs of the patients. Therefore this kind of experience can provide a long-term benefit to the company in building their business and creating new business models.
Click here to download the full report on the pilot activity